CD22 and hematologic disorder: For this proof of concept, two different CARm-encoding CAR tool constructs specific for antigens that are expressed in hematological malignancies (tool CAR123 and tool CAR22, which are specific for CD123 and CD22, respectively) were used to assess the robustness of our engineering strategy.